GO:0072582 17-beta-hydroxysteroid dehydrogenase (NADP+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072582 defines the NADP+-dependent molecular function that interconverts a 17-beta-hydroxysteroid and a 17-oxosteroid, producing NADPH and H+.
• The reaction is reversible and cofactor-specific: NADP+ is the preferred cofactor in many tissue preparations, distinguishing this activity from NAD+-dependent 17-beta-HSD reactions.
• Activity levels correlate with mRNA abundance of type-2 17-beta-HSD in human meningioma tumors, linking transcriptional control to net steroid conversion.
• The same catalytic activity can be associated with multiple protein forms, as shown by isolation of several indanol dehydrogenase forms with 17-beta-HSD activity from rabbit liver.
• Altered 17-beta-HSD activity has been reported in polycystic ovarian tissue and in maternal and umbilical cord sera, indicating endocrine and developmental relevance.
• Inhibitors of 17-beta-hydroxysteroid dehydrogenases are actively pursued as chemical tools and potential therapeutics, making this GO term a drug-discovery target.
Description
17-beta-hydroxysteroid dehydrogenase (NADP+) activity (GO:0072582) is a molecular function that catalyzes the reversible oxidoreduction of a 17-beta-hydroxysteroid to a 17-oxosteroid using NADP+ as the electron acceptor, releasing NADPH and H+. This activity is central to steroid hormone metabolism because it controls the balance between active 17-beta-hydroxy steroids and their 17-keto counterparts in peripheral tissues. Researchers study GO:0072582 to understand how local steroid activation and inactivation are regulated, and how this balance contributes to endocrine physiology and disease. The term is defined by its chemistry rather than by a single gene product: multiple enzymes can display this activity, and the same activity can be measured in different subcellular fractions and tissues. Cofactor dependency is a key experimental criterion, and NADP+ preference has been documented in cultured myometrial cells and in serum-based assays. Because the reaction is reversible, net direction depends on substrate availability, cofactor ratios, and the complement of expressed enzyme isoforms. From a translational perspective, GO:0072582 is relevant to hormone-dependent tumors, reproductive disorders, and drug discovery. Quantitative readouts of this activity, together with mRNA abundance measurements, provide a framework for linking genotype to steroid output. This article summarizes the definition, mechanism, key genes, disease links, and experimental models used to interrogate this activity.
17-beta-hydroxysteroid dehydrogenase (NADP+) activity At A Glance
| GO ID | GO:0072582 |
|---|---|
| GO term | 17-beta-hydroxysteroid dehydrogenase (NADP+) activity |
| Ontology | molecular_function |
| Synonym | (none) |
| Major function | Catalysis of the reversible interconversion of a 17-beta-hydroxysteroid and a 17-oxosteroid using NADP+ as cofactor, producing NADPH and H+ |
| Reaction direction | Reversible; net direction depends on substrate and cofactor availability |
| Cofactor | NADP+ (NADPH generated); NADP+ preference distinguishes this activity from NAD+-dependent reactions |
| Subcellular context | Activity has been characterized in subcellular fractions of cultured myometrial cells |
| Tissue examples | Human meningioma tumors, ovarian tissue, maternal and umbilical cord sera, guinea-pig and rabbit liver |
| Disease relevance | Hormone-dependent tumors, polycystic ovary tissue, endocrine and developmental biology |
What Is GO:0072582?
GO:0072582 describes catalysis of the reaction: a 17-beta-hydroxysteroid + NADP+ = a 17-oxosteroid + NADPH + H+. In practical terms, the enzyme removes a hydride from the 17-beta-hydroxy group of a steroid and transfers it to NADP+, generating a 17-oxo (keto) steroid, NADPH, and a proton. The reaction is reversible, so the same activity can also reduce a 17-oxosteroid back to a 17-beta-hydroxysteroid when NADPH is available. This function is defined by its cofactor preference for NADP+ and by the steroid 17-position chemistry, not by a single protein sequence.
Why Is 17-beta-hydroxysteroid dehydrogenase (NADP+) activity Important in Cell Biology?
GO:0072582 is important because it defines a chemically precise, cofactor-specific step in steroid hormone metabolism that can be measured, inhibited, and genetically dissected. It provides a common annotation language for enzymes that may differ in sequence but share NADP+-dependent 17-beta-hydroxysteroid oxidoreduction, enabling cross-study comparison of activity data and mRNA abundance. Because the reaction is reversible and tissue-specific, it is a focal point for understanding local hormone activation and inactivation in tumors, reproductive tissues, and serum compartments.
• Provides a standardized GO annotation for NADP+-dependent 17-beta-hydroxysteroid oxidoreduction, enabling consistent data integration.
• Links enzyme activity to mRNA abundance of type-2 17-beta-HSD in human meningioma tumors.
• Supports studies of hormone-dependent cancers where local steroid conversion affects tumor biology.
• Enables investigation of reproductive disorders such as polycystic ovary tissue alterations in 17-beta-hydroxysteroid oxidoreductase activity.
• Facilitates analysis of maternal and umbilical cord serum steroid metabolism during development.
• Guides inhibitor discovery programs targeting 17-beta-hydroxysteroid dehydrogenases.
• Helps distinguish NADP+-dependent activity from NAD+-dependent reactions in subcellular fractions.
• Explains how multiple protein forms can contribute to a single measured activity in tissue extracts.
• Provides a biochemical endpoint for CRISPR knockout, knock-in, and overexpression validation.
• Connects basic enzymology to endocrine physiology and drug development.
Molecular Mechanism of 17-beta-hydroxysteroid dehydrogenase (NADP+) activity
Substrate recognition and 17-position chemistry
In simple terms: The enzyme finds the 17-beta-hydroxy group on a steroid and prepares it for chemical conversion.
The activity is defined by the steroid 17-position: a 17-beta-hydroxysteroid is the substrate for oxidation, and a 17-oxosteroid is the product. Substrate specificity has been characterized in tissue preparations, including human meningioma tumors and cultured myometrial cells, where activity correlates with the abundance of type-2 17-beta-HSD mRNA. Because the reaction is reversible, the same active site can bind either the hydroxy or the keto form depending on conditions.
Cofactor binding and NADP+ preference
In simple terms: The enzyme uses NADP+ as its helper molecule, taking a hydride from the steroid and converting NADP+ to NADPH.
Cofactor dependency studies in cultured myometrial cells established that the activity can use NADP+, generating NADPH and H+. Serum-based measurements of 17-beta-hydroxysteroid oxidoreductase activity further support the presence of this cofactor-dependent reaction in biological fluids. The NADP+ preference is a defining feature of GO:0072582 and helps distinguish it from NAD+-dependent 17-beta-HSD activities.
Catalytic cycle and reversibility
In simple terms: The enzyme can run the reaction forward or backward, so the final steroid balance depends on what substrates and cofactors are available.
The catalytic cycle interconverts a 17-beta-hydroxysteroid and a 17-oxosteroid while cycling NADP+ and NADPH. Reversibility has been documented in tissue and serum assays, where the net direction reflects local substrate and cofactor concentrations. In human meningioma tumors, activity levels correlate with type-2 17-beta-HSD mRNA abundance, suggesting that enzyme expression is a major determinant of net flux.
Multiple enzyme forms contributing to one activity
In simple terms: Different proteins can perform the same chemical reaction, so a single activity measurement may reflect several enzymes.
Isolation of multiple forms of indanol dehydrogenase associated with 17-beta-hydroxysteroid dehydrogenase activity from male rabbit liver demonstrated that one measured activity can arise from more than one protein species. Guinea-pig liver testosterone 17-beta-dehydrogenase (NADP+) also exhibits benzene dihydrodiol dehydrogenase activity, showing that catalytic promiscuity can accompany this GO function. This heterogeneity means that activity assays should be interpreted alongside mRNA and protein data.
Tissue and subcellular context
In simple terms: Where the enzyme sits in the cell and which tissue it is in affects how much activity is measured.
Subcellular localization and cofactor dependency were characterized in cultured myometrial cells, providing a framework for interpreting activity in different fractions. Activity has also been measured in human ovarian tissue, maternal and umbilical cord sera, and meningioma tumors, indicating broad tissue distribution. These context-dependent measurements are essential for comparing normal and diseased tissues.
Key Genes Involved in GO:0072582 17-beta-hydroxysteroid dehydrogenase (NADP+) activity
The following genes and protein entries are associated with 17-beta-hydroxysteroid dehydrogenase (NADP+) activity or with the measurement of this activity in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HSD17B2 | Type-2 17-beta-HSD; mRNA abundance correlates with 17-beta-HSD activity in meningioma tumors | Used to link transcript levels to measured NADP+-dependent activity |
| HSD17B1 | 17-beta-HSD isoform studied in inhibitor development | Target for chemical inhibitors of 17-beta-HSD activity |
| HSD17B3 | 17-beta-HSD isoform discussed in inhibitor reviews | Relevant to steroid conversion and drug discovery |
| HSD17B5 | 17-beta-HSD isoform discussed in inhibitor reviews | Relevant to steroid conversion and drug discovery |
| HSD17B7 | 17-beta-HSD isoform discussed in inhibitor reviews | Relevant to steroid conversion and drug discovery |
| HSD17B10 | 17-beta-HSD isoform discussed in inhibitor reviews | Relevant to steroid conversion and drug discovery |
| AKR1C1 | Aldo-keto reductase with 17-beta-HSD activity discussed in inhibitor reviews | Potential off-target or alternative enzyme for this activity |
| AKR1C2 | Aldo-keto reductase with 17-beta-HSD activity discussed in inhibitor reviews | Potential off-target or alternative enzyme for this activity |
| AKR1C3 | Aldo-keto reductase with 17-beta-HSD activity discussed in inhibitor reviews | Potential off-target or alternative enzyme for this activity |
| AKR1B1 | Aldehyde reductase with benzene dihydrodiol dehydrogenase activity and 17-beta-HSD activity in guinea-pig liver | Example of catalytic promiscuity associated with this activity |
| Indanol dehydrogenase forms | Multiple forms isolated from male rabbit liver with 17-beta-HSD activity | Demonstrates protein heterogeneity behind one activity |
| Type-2 17-beta-HSD | Enzyme whose mRNA abundance correlates with activity in human meningioma tumors | Key marker for activity-transcript correlation studies |
| Ovarian 17-beta-hydroxysteroid oxidoreductase | Activity measured in normal and polycystic ovarian tissues | Model for reproductive disorder research |
| Serum 17-beta-hydroxysteroid oxidoreductase | Activity measured in maternal and umbilical cord sera | Model for developmental and endocrine studies |
| Myometrial 17-beta-HSD | Activity characterized for cofactor dependency and subcellular localization | Model for cell-based mechanistic studies |
How Is 17-beta-hydroxysteroid dehydrogenase (NADP+) activity Regulated?
Regulation of 17-beta-hydroxysteroid dehydrogenase (NADP+) activity appears to involve both transcriptional and post-transcriptional layers. In human meningioma tumors, activity levels correlate with the abundance of type-2 17-beta-HSD mRNA, indicating that transcript availability is a major determinant of measured activity. Cofactor availability provides a second layer of control, since the reaction requires NADP+ and produces NADPH, and cofactor dependency has been directly characterized in cultured myometrial cells. Tissue-specific expression of multiple enzyme forms, as shown by isolation of several indanol dehydrogenase forms with this activity from rabbit liver, adds a third layer of regulation through protein composition. Finally, the reversible nature of the reaction means that substrate and product concentrations can shift net flux without changes in enzyme abundance.
17-beta-hydroxysteroid dehydrogenase (NADP+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HSD17B2 | Meningioma; activity correlates with mRNA abundance | Knockout or overexpression in meningioma cell lines with activity assay |
| HSD17B1 | Hormone-dependent cancer; inhibitor target | Point mutation of catalytic residues followed by activity measurement |
| HSD17B3 | Steroid metabolism; inhibitor target | Knock-in of tagged enzyme for localization and activity studies |
| AKR1C3 | Steroid metabolism; alternative enzyme for this activity | Knockout to isolate contribution to total activity |
| Ovarian 17-beta-HSD | Polycystic ovary tissue; altered activity | Primary ovarian tissue or cell model with activity assay |
Meningioma and hormone-dependent tumors
In human meningioma tumors, 17-beta-hydroxysteroid dehydrogenase activity correlates with the mRNA abundance of type-2 17-beta-HSD, suggesting that local steroid conversion may contribute to tumor biology. These findings support the use of activity and transcript measurements as paired readouts in hormone-dependent tumor research. Inhibitors of 17-beta-hydroxysteroid dehydrogenases are being explored as tools to probe and potentially modulate such pathways.
Polycystic ovary and reproductive disorders
Human ovarian 17-beta-hydroxysteroid oxidoreductase activity has been compared between normal and polycystic ovarian tissues, providing evidence that this activity is altered in reproductive pathology. Because the reaction controls the balance between 17-beta-hydroxy and 17-oxo steroids, changes in activity could influence local hormone availability. This makes GO:0072582 a relevant annotation for studies of ovarian endocrine dysfunction.
Developmental and maternal-fetal endocrinology
17-beta-hydroxysteroid oxidoreductase activity has been measured in human maternal and umbilical cord sera, indicating that this activity is present in the maternal-fetal compartment. Such measurements are relevant to understanding steroid metabolism during pregnancy and development. The NADP+ dependence of the activity provides a biochemical handle for comparing serum samples across clinical states.
Drug discovery and inhibitor development
Inhibitors of 17-beta-hydroxysteroid dehydrogenases have been reviewed as chemical tools and potential therapeutics, making GO:0072582 a target annotation in medicinal chemistry. Because multiple isoforms can contribute to the same activity, inhibitor selectivity is a central challenge. Activity assays linked to mRNA abundance provide a way to interpret inhibitor effects in relevant tissues.
From 17-beta-hydroxysteroid dehydrogenase (NADP+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene reduce NADP+-dependent 17-beta-HSD activity? | CRISPR knockout cell line with activity assay |
| Does a specific residue control cofactor preference? | Point mutation of candidate catalytic residues followed by NADP+ vs NAD+ assays |
| Can a tagged enzyme be tracked in subcellular fractions? | Knock-in of an epitope tag for localization and activity measurement |
| Does overexpression increase net steroid conversion? | Overexpression cell model with substrate conversion assay |
| Which isoforms contribute to total activity in a tissue? | Knockout panel or library screening with activity readout |
| Is activity altered in disease tissue? | Patient-derived or disease-model cells compared with normal controls |
How to Study the 17-beta-hydroxysteroid dehydrogenase (NADP+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADPH generation assay | Rate of NADP+ reduction during steroid oxidation | Quantify 17-beta-HSD activity in cell lysates |
| Steroid product quantification | Conversion of 17-beta-hydroxysteroid to 17-oxosteroid | Measure net activity and reversibility |
| qRT-PCR for type-2 17-beta-HSD | mRNA abundance | Correlate transcript levels with activity |
| Subcellular fractionation | Distribution of activity across compartments | Determine localization of the enzyme |
| Chromatographic isoform separation | Number and identity of active protein forms | Resolve multiple enzymes contributing to one activity |
| Serum activity assay | Activity in maternal and umbilical cord sera | Study developmental and endocrine states |
| Inhibitor titration | Sensitivity of activity to chemical inhibitors | Evaluate selectivity and drug-discovery potential |
| Tissue comparison assay | Activity in normal versus diseased tissue | Study polycystic ovary and tumor biology |
Enzyme activity assays with NADP+
Direct measurement of 17-beta-hydroxysteroid dehydrogenase (NADP+) activity uses substrate conversion monitored by NADPH generation or steroid product formation. Cofactor dependency should be tested by comparing NADP+ and NAD+ conditions, as established in cultured myometrial cells. Activity in serum or tissue extracts can be measured with appropriate controls for background oxidoreductase activity.
mRNA abundance and transcript correlation
Quantitative mRNA measurements, such as type-2 17-beta-HSD transcript levels, can be correlated with measured activity to infer transcriptional control. This paired approach has been applied in human meningioma tumors and provides a template for other tissues. Transcript data also help interpret whether changes in activity reflect enzyme abundance or cofactor availability.
Protein resolution and isoform analysis
Because multiple protein forms can contribute to a single activity, chromatographic or electrophoretic resolution of enzyme forms is valuable. Isolation of indanol dehydrogenase forms with 17-beta-HSD activity from rabbit liver illustrates this strategy. Such work helps assign measured activity to specific gene products and supports inhibitor selectivity studies.
Subcellular fractionation and localization
Subcellular localization studies, as performed in cultured myometrial cells, clarify where the activity resides within the cell. Fractionation combined with activity assays can distinguish membrane-associated from soluble contributions. These data are essential for interpreting CRISPR knockout phenotypes in compartment-specific contexts.
How CRISPR Can Be Used to Study GO:0072582 17-beta-hydroxysteroid dehydrogenase (NADP+) activity
Knockout
CRISPR knockout of candidate genes such as HSD17B2 or AKR1C3 can test whether loss of a specific enzyme reduces total NADP+-dependent 17-beta-HSD activity. Because multiple protein forms can contribute to the same activity, knockout panels are useful to assign fractional contributions. Activity assays in knockout lysates should be paired with mRNA measurements to confirm target loss.
Point Mutation
Point mutation of candidate catalytic residues can test cofactor preference and mechanism, given that NADP+ dependence is a defining feature of GO:0072582. Mutants can be compared in parallel NADP+ and NAD+ assays to determine whether cofactor specificity is altered. Such experiments help distinguish this activity from related NAD+-dependent reactions.
Knock-in
Knock-in of epitope or fluorescent tags allows localization and purification of the enzyme while preserving endogenous regulation. Tagged knock-in lines can be used for subcellular fractionation studies that mirror earlier myometrial cell work. This approach is particularly useful when multiple isoforms contribute to the same activity.
Overexpression
Overexpression of a candidate enzyme can test whether increased protein abundance raises net steroid conversion in cells. Overexpression models are useful when baseline activity is low or when testing substrate flux in a defined background. Results should be interpreted alongside mRNA and activity data from disease tissues.
How EDITGENE Supports 17-beta-hydroxysteroid dehydrogenase (NADP+) activity Research
Researchers studying 17-beta-hydroxysteroid dehydrogenase (NADP+) activity-related genes often need to determine whether a candidate gene is causally involved in the measured activity, whether a specific residue controls cofactor preference, and whether altered expression changes net steroid conversion. EDITGENE provides CRISPR-based cell models and screening services designed to answer these questions with publication-ready validation.
Contact EDITGENE today to design your custom CRISPR model for 17-beta-hydroxysteroid dehydrogenase (NADP+) activity research.
Frequently Asked Questions About 17-beta-hydroxysteroid dehydrogenase (NADP+) activity
What is 17-beta-hydroxysteroid dehydrogenase (NADP+) activity?
It is the molecular function defined by GO:0072582, catalyzing the reversible conversion of a 17-beta-hydroxysteroid to a 17-oxosteroid using NADP+ as cofactor, producing NADPH and H+.
What is the GO ID for 17-beta-hydroxysteroid dehydrogenase (NADP+) activity?
The GO ID is GO:0072582, classified under the molecular_function ontology.
What genes are involved in 17-beta-hydroxysteroid dehydrogenase (NADP+) activity?
Genes discussed in the literature include HSD17B2, whose mRNA abundance correlates with activity in meningioma tumors, and several HSD17B and AKR1C isoforms discussed in inhibitor reviews.
How is 17-beta-hydroxysteroid dehydrogenase (NADP+) activity measured?
Activity is typically measured by NADPH generation or steroid product formation, with cofactor dependency tested by comparing NADP+ and NAD+ conditions.
Why is NADP+ important for this activity?
NADP+ is the electron acceptor in the reaction, and its preference distinguishes GO:0072582 from NAD+-dependent 17-beta-HSD activities.
Is 17-beta-hydroxysteroid dehydrogenase (NADP+) activity reversible?
Yes, the reaction is reversible, and net direction depends on substrate and cofactor availability in the tissue or cell context.
What diseases are linked to 17-beta-hydroxysteroid dehydrogenase (NADP+) activity?
Links have been reported to meningioma, polycystic ovary tissue, and maternal-fetal endocrine states, and inhibitors are being explored for hormone-dependent conditions.
Can multiple enzymes perform 17-beta-hydroxysteroid dehydrogenase (NADP+) activity?
Yes, isolation of multiple indanol dehydrogenase forms with this activity from rabbit liver shows that more than one protein can contribute to a single measured activity.
How do CRISPR knockouts help study this activity?
Knockouts of candidate genes allow researchers to test whether loss of a specific enzyme reduces total NADP+-dependent activity and to assign fractional contributions.
What cell models are useful for studying this activity?
Cell models include knockout, point-mutation, knock-in, and overexpression lines, as well as disease-relevant cells such as meningioma and ovarian tissue models.
Conclusion
GO:0072582 defines a chemically precise, NADP+-dependent steroid oxidoreduction that is central to local hormone metabolism and is measurable across tumors, reproductive tissues, and serum compartments. Because multiple protein forms can contribute to the same activity, careful pairing of activity assays with mRNA and protein data is essential for correct interpretation. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide a direct route to causal testing of candidate genes and residues.
References
- 1. Carsol JL et al.. 1996. 17 beta-Hydroxysteroid dehydrogenase activity correlates with the type-2 17 beta-hydroxysteroid dehydrogenase mRNA abundance in human meningioma tumors.. Neuroendocrinology 64(1):70-8 PMID: 8811669
- 2. Carsol JL et al.. 1994. Characterization of 17 beta-hydroxysteroid dehydrogenase activity and mRNA abundance in human meningioma tumors.. Neuroendocrinology 60(4):445-51 PMID: 7824086
- 3. Hara A et al.. 1985. Guinea-pig liver testosterone 17 beta-dehydrogenase (NADP+) and aldehyde reductase exhibit benzene dihydrodiol dehydrogenase activity.. Biochem J 225(1):177-81 PMID: 2983661
- 4. Vallet-Strouve C et al.. 1983. Further characterization of 17 beta-hydroxysteroid dehydrogenase activity in cultured myometrial cells: cofactor dependency and subcellular localization.. Steroids 42(5):525-37 PMID: 6597656
- 5. Poirier D. 2003. Inhibitors of 17 beta-hydroxysteroid dehydrogenases.. Curr Med Chem 10(6):453-77 PMID: 12570693
- 6. Pittaway DE et al.. 1983. Human ovarian 17 beta-hydroxysteroid oxidoreductase activity: a comparison of normal and polycystic ovarian tissues.. J Clin Endocrinol Metab 56(4):715-9 PMID: 6300163
- 7. Hara A et al.. 1986. Isolation of multiple forms of indanol dehydrogenase associated with 17 beta-hydroxysteroid dehydrogenase activity from male rabbit liver.. Arch Biochem Biophys 249(1):225-36 PMID: 3527067
- 8. Milewich L et al.. 1990. 17 beta-Hydroxysteroid oxidoreductase activity in human maternal and umbilical cord sera.. J Steroid Biochem 35(1):67-75 PMID: 2155349
